Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.
University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China.
J Gastroenterol. 2024 Dec;59(12):1053-1078. doi: 10.1007/s00535-024-02157-0. Epub 2024 Oct 14.
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a multifaceted liver disease characterized by inflammation and fibrosis that develops from simple steatosis. Immune and inflammatory pathways have a central role in the pathogenesis of MASH, yet, how to target immune pathways to treat MASH remains perplexed. This review emphasizes the intricate role that immune cells play in the etiology and pathophysiology of MASH and highlights their significance as targets for therapeutic approaches. It discusses both current strategies and novel therapies aimed at modulating the immune response in MASH. It also highlights challenges in liver-specific drug delivery, potential off-target effects, and difficulties in targeting diverse immune cell populations within the liver. This review is a comprehensive resource that integrates current knowledge with future perspectives in the evolving field of MASH, with the goal of driving forward progress in medical therapies designed to treat this complex liver disease.
代谢相关脂肪性肝炎（MASH），以前称为非酒精性脂肪性肝炎（NASH），是一种多方面的肝脏疾病，其特征为炎症和纤维化，由单纯性脂肪变性发展而来。免疫和炎症途径在 MASH 的发病机制中起着核心作用，然而，如何针对免疫途径来治疗 MASH 仍然令人困惑。这篇综述强调了免疫细胞在 MASH 的病因学和病理生理学中所扮演的复杂角色，并强调了它们作为治疗方法靶点的重要性。它讨论了目前旨在调节 MASH 免疫反应的策略和新疗法，并强调了肝脏特异性药物递送中的挑战、潜在的脱靶效应以及在肝脏内靶向不同免疫细胞群体的困难。这篇综述是一个综合资源，它将当前的知识与 MASH 这一不断发展领域的未来观点相结合，旨在推动旨在治疗这种复杂肝脏疾病的医学治疗方法的进展。
